Tissium
Tissium (formerly Gecko Biomedical) is a privately owned medical device company based in Paris that is dedicated to the rapid development and commercialization of a unique biopolymers platform.
Tissium’s first product (GB-02) is an innovative polymer for tissue healing, targeting cardiovascular reconstruction as an initial indication. The structure of GB-02 is tunable, allowing customization for various applications and tissues. Gecko’s biopolymers platform is fully industrialized and highly versatile, with potential novel applications in other fields of tissue reconstruction, such as guided tissue repair and localized drug delivery.
Tissium’s platform is based on proprietary biopolymers with unique chemical and physical properties, including high viscosity, hydrophobicity and fast “on demand” curing for precise local delivery and in situ adhesion.
Sector
Medical Devices
Strategy
Capital
Status
Live
Website
tissium.com
Related News
TISSIUM Raises €50M in Series D funding to finance its commercial launch and platform extension
TISSIUM appoints Sara Toyloy as independent Board member
Tissium appoints Maria Sainz as Independent Board Member
5 Sofinnova Partners portfolio companies selected to French Tech 120
TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.